Background

The EU has set a goal to expand clinical trials to one million studies by 2030 and increase data transparency. This report evaluates the actual progress to verify policy effectiveness. Standardizing data across member states and implementing digital platforms are essential for achieving the target. The importance of this goal lies in its direct link to accelerating drug development and reducing costs.

Current Progress

According to the report, the total number of clinical trials in 2023 was approximately 650,000, representing about 65% of the target. Utilization of the clinical trial information system (CTIS) as a data‑sharing platform has risen to over 80%. However, some countries are experiencing delays in data entry due to insufficient infrastructure. These gaps could influence drug accessibility across the entire EU market.

Impact on Industry and Patients

Greater transparency of clinical trial data enables pharmaceutical and biotech companies to streamline study design and patient recruitment. Patients, in turn, have a higher likelihood of finding suitable trials quickly. Multinational collaboration is expected to expand especially in the rare‑disease space, lowering market entry barriers and shortening investment payback periods.

Future Challenges and Outlook

Achieving the remaining objectives will require continued data standardization and regulatory harmonization, as well as stronger collaboration mechanisms among member states. Additional investment in digital infrastructure and targeted training programs are also needed. If these measures succeed, the EU can significantly enhance its competitiveness as a global clinical‑trial hub.